SCHEMBL510241

SCHEMBL510241

COc1ccc(C)c(-c2cc3ccc(C)cc3c(N)n2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 2/20 0.43
RAD52 P43351 1/20 0.42
MAP4K1 Q92918 2/20 0.42
HSP90AA1 P07900 3/20 0.40
HSP90AB1 P08238 2/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
SYK P43405 1/20 0.38
ACHE P22303 1/20 0.38
NCF1 P14598 1/20 0.37
NPC1 O15118 2/20 0.37
DYRK1A Q13627 1/20 0.36
CASP3 P42574 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL509299 0.89 RAD52 (0.45) DHFRRAD52HSP90AA1HSP90AB1KDM4E
SCHEMBL509858 0.82 SYK (0.56) KDM4EALDH1A1SYKNPC1DYRK1A
SCHEMBL509124 0.79 NPC1 (0.47) RAD52ALDH1A1HPGDHSD17B10SYK
SCHEMBL509116 0.79 DHFR (0.46) DHFRRAD52MAP4K1HSP90AA1KDM4E
SCHEMBL509138 0.78 SCN2A (0.48) KDM4EALDH1A1HPGDHSD17B10SYK
SCHEMBL509700 0.78 RAD52 (0.48) DHFRRAD52MAP4K1HSP90AA1HSP90AB1
SCHEMBL509476 0.77 HSP90AA1 (0.56) DHFRRAD52HSP90AA1HSP90AB1KDM4E
SCHEMBL3830028 0.76 NPC1 (0.55) CYP11B1CYP11B2NPC1CASP3RAB9A
SCHEMBL510079 0.73 AGPAT2 (0.52) DHFRRAD52HSP90AA1HSP90AB1ALDH1A1
SCHEMBL508363 0.72 CYP1A2 (0.50) DHFRKDM4EALDH1A1LMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314123-B2 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2012-11-20 US disclosed
EP-2423196-A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof Rexahn Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF REXAHN PHARMACEUTICALS, INC. (US) 2012-02-02 US disclosed
US-8034829-B2 e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. REXAHN PHARMACEUTICALS, INC. (US) 2011-10-11 US disclosed
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof REXAHN PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182871-A1 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof FANCD2, NRAS, CCND2 DHFR 178/4885RAD52 542/4885MAP4K1 1385/4885
US-20120029012-A1 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF FANCD2, NRAS, CCND2 DHFR 178/4885RAD52 542/4885MAP4K1 1385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.